{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:12Z","timestamp":1791352212994,"version":"4.3.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":2937,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1074\/jbc.m112.399725","type":"journal-article","created":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T05:07:49Z","timestamp":1344488869000},"page":"33745-33755","source":"Crossref","is-referenced-by-count":81,"title":["Loss- and Gain-of-function PCSK9 Variants"],"prefix":"10.1016","volume":"287","author":[{"given":"Suzanne","family":"Benjannet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e","family":"Hamelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil G.","family":"Seidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.M112.399725_bib1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.biocel.2008.01.030","article-title":"The activation and physiological functions of the proprotein convertases","volume":"40","author":"Seidah","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1074\/jbc.M112.399725_bib2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1074\/jbc.M112.399725_bib3","doi-asserted-by":"crossref","DOI":"10.1139\/o2012-031","article-title":"My road to Damascus: how I converted to the prohormone theory and the proprotein convertases","author":"Chr\u00e9tien","year":"2012","journal-title":"Biochem. Cell Biol."},{"key":"10.1074\/jbc.M112.399725_bib4","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1074\/jbc.M112.399725_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1074\/jbc.M112.399725_bib6","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1074\/jbc.M112.399725_bib7","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1074\/jbc.M112.399725_bib8","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"Nassoury","year":"2007","journal-title":"Traffic"},{"key":"10.1074\/jbc.M112.399725_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.abb.2003.09.011","article-title":"Functional characterization of Narc 1, a novel proteinase related to proteinase K","volume":"420","author":"Naureckiene","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1074\/jbc.M112.399725_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1074\/jbc.M112.399725_bib12","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/BJ20070664","article-title":"Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity","volume":"406","author":"Li","year":"2007","journal-title":"Biochem. J."},{"key":"10.1074\/jbc.M112.399725_bib14","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib15","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1373\/clinchem.2011.165191","article-title":"Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture","volume":"57","author":"Mayne","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1074\/jbc.M112.399725_bib16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1074\/jbc.M112.399725_bib17","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1074\/jbc.M112.399725_bib18","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Surdo","year":"2011","journal-title":"EMBO Rep."},{"key":"10.1074\/jbc.M112.399725_bib19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00439-003-1071-9","article-title":"A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree","volume":"114","author":"Timms","year":"2004","journal-title":"Hum. Genet."},{"key":"10.1074\/jbc.M112.399725_bib20","doi-asserted-by":"crossref","first-page":"20502","DOI":"10.1074\/jbc.M701634200","article-title":"PCSK9-dependent LDL receptor regulation: effects of pH and LDL","volume":"282","author":"Fisher","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib21","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1074\/jbc.M112.399725_bib22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2008.10.027","article-title":"Degradation of LDLR protein mediated by \u2018gain of function\u2019 PCSK9 mutants in normal and ARH cells","volume":"203","author":"Fasano","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1074\/jbc.M112.399725_bib23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.atherosclerosis.2007.07.019","article-title":"Familial hypercholesterolaemia in Portugal","volume":"196","author":"Bourbon","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1074\/jbc.M112.399725_bib24","doi-asserted-by":"crossref","first-page":"10879","DOI":"10.1074\/jbc.M009899200","article-title":"Post-translational processing of \u03b2-secretase (\u03b2-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane\/cytosolic domains affect its cellular activity and amyloid-\u03b2 production","volume":"276","author":"Benjannet","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib25","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.1146361","article-title":"IRE1 signaling affects cell fate during the unfolded protein response","volume":"318","author":"Lin","year":"2007","journal-title":"Science"},{"key":"10.1074\/jbc.M112.399725_bib26","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0092-8674(01)00611-0","article-title":"XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor","volume":"107","author":"Yoshida","year":"2001","journal-title":"Cell"},{"key":"10.1074\/jbc.M112.399725_bib27","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1074\/jbc.M112.399725_bib29","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1074\/jbc.M110.192104","article-title":"In vivo evidence that furin from hepatocytes inactivates PCSK9","volume":"286","author":"Essalmani","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1074\/jbc.M112.399725_bib31","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1074\/jbc.M110.192344","article-title":"The proprotein convertase PC7: unique zymogen activation and trafficking pathways","volume":"286","author":"Rousselet","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib32","doi-asserted-by":"crossref","first-page":"40965","DOI":"10.1074\/jbc.M110.154815","article-title":"Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events","volume":"285","author":"Benjannet","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib33","doi-asserted-by":"crossref","first-page":"33913","DOI":"10.1074\/jbc.274.48.33913","article-title":"The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitroex vivo assessment of their efficacy and selectivity","volume":"274","author":"Zhong","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib34","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1074\/jbc.M208009200","article-title":"Structure-function analysis of the prosegment of the proprotein convertase PC5A","volume":"278","author":"Nour","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib35","doi-asserted-by":"crossref","first-page":"17338","DOI":"10.1074\/jbc.M313764200","article-title":"Development of protein-based inhibitors of the proprotein of convertase SKI-1\/S1P: processing of SREBP-2, ATF6, and a viral glycoprotein","volume":"279","author":"Pullikotil","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib36","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/pro.5560060301","article-title":"Subtilases: the superfamily of subtilisin-like serine proteases","volume":"6","author":"Siezen","year":"1997","journal-title":"Protein Sci."},{"key":"10.1074\/jbc.M112.399725_bib37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1074\/jbc.M112.399725_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1665-2681(19)31564-9","article-title":"Familial hypobetalipoproteinemia in a hospital survey: genetics, metabolism and non-alcoholic fatty liver disease","volume":"10","author":"Guti\u00e9rrez-Cirlos","year":"2011","journal-title":"Ann. Hepatol."},{"key":"10.1074\/jbc.M112.399725_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-61779-204-5_4","article-title":"Insights from bacterial subtilases into the mechanisms of intramolecular chaperone-mediated activation of furin","volume":"768","author":"Shinde","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1074\/jbc.M112.399725_bib40","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1194\/jlr.M800049-JLR200","article-title":"Functional analysis of sites within PCSK9 responsible for hypercholesterolemia","volume":"49","author":"Pandit","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1074\/jbc.M112.399725_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14728220802600715","article-title":"PCSK9 as a therapeutic target of dyslipidemia","volume":"13","author":"Seidah","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"issue":"suppl.","key":"10.1074\/jbc.M112.399725_bib42","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1074\/jbc.M112.399725_bib43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/ATVBAHA.110.209007","article-title":"Beyond LDL cholesterol, a new role for PCSK9","volume":"30","author":"Akram","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1074\/jbc.M112.399725_bib44","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake","volume":"285","author":"Ni","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2012.06.018","article-title":"Calcium-independent inhibition of PCSK9 by affinity-improved variants of the LDL receptor EGF(A) domain","author":"Zhang","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1074\/jbc.M112.399725_bib46","doi-asserted-by":"crossref","first-page":"31791","DOI":"10.1074\/jbc.M805971200","article-title":"Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels","volume":"283","author":"Mayer","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1074\/jbc.M112.399725_bib47","doi-asserted-by":"crossref","first-page":"e41865","DOI":"10.1371\/journal.pone.0041865","article-title":"Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation","volume":"7","author":"Seidah","year":"2012","journal-title":"PLoS One"},{"key":"10.1074\/jbc.M112.399725_bib48","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1021\/bi802232m","article-title":"Binding to low-density lipoprotein receptor accelerates futile catalytic cycling in PCSK9 and raises the equilibrium level of intramolecular acylenzyme","volume":"48","author":"Geoghegan","year":"2009","journal-title":"Biochemistry"},{"key":"10.1074\/jbc.M112.399725_bib49","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1074\/jbc.M112.399725_bib50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1074\/jbc.M112.399725_bib51","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.atherosclerosis.2012.04.006","article-title":"Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia","volume":"223","author":"Abifadel","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1074\/jbc.M112.399725_bib52","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/hmg\/ddi128","article-title":"Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia","volume":"14","author":"Sun","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1074\/jbc.M112.399725_bib53","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1074\/jbc.M808802200","article-title":"Antagonism of secreted PCSK9 increases low-density lipoprotein receptor expression in HEPG2 cells","volume":"284","author":"McNutt","year":"2009","journal-title":"J. Biol. Chem."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820628745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820628745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.M112.399725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T03:51:14Z","timestamp":1624074674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820628745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":53,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0021925820628745"],"URL":"https:\/\/doi.org\/10.1074\/jbc.m112.399725","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}